Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00242411 |
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Budesonide/Formoterol Turbuhaler Drug: Conventional Best Asthma Therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus as-Needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-Group, Multicentre 26-Weeks Study |
Estimated Enrollment: | 1900 |
Study Start Date: | September 2004 |
Study Completion Date: | October 2006 |
Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Additional inclusion and exclusion criteria will be evaluated by the investigator.
Study Director: | AstraZeneca Symbicort Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D5890L00008 |
Study First Received: | October 18, 2005 |
Last Updated: | January 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00242411 History of Changes |
Health Authority: | Denmark: Danish Medicines Agency |
Hypersensitivity Lung Diseases, Obstructive Symbicort Respiratory Tract Diseases Bronchial Diseases Lung Diseases |
Budesonide Hypersensitivity, Immediate Anti-Asthmatic Agents Formoterol Asthma Respiratory Hypersensitivity |
Respiratory System Agents Bronchial Diseases Immune System Diseases Symbicort Asthma Anti-Asthmatic Agents Pharmacologic Actions |
Lung Diseases, Obstructive Hypersensitivity Respiratory Tract Diseases Lung Diseases Therapeutic Uses Hypersensitivity, Immediate Respiratory Hypersensitivity |